4月14日 - ** 生物技术公司 Anavex Life Sciences AVXL.O 股价盘前上涨 1.3% 至 3.15 美元
** 该公司称，在新研究表明自闭症和阿尔茨海默氏症具有相似的潜在生物学特性后，它计划对其实验性药物blarcamesine进行关键性试验。
** 研究表明，这两种疾病都存在 "细胞清理 "问题，即脑细胞难以清除废物。
** 补充说，blarcamesine针对一种蛋白质，帮助恢复这种细胞清理过程，研究显示它对阿尔茨海默氏症和雷特综合征有好处
** 雷特综合征是一种罕见的儿童神经系统疾病，会影响大脑发育，尤其是女孩，并导致失语和运动障碍。
** 截至上一交易日收盘，股价年累计下跌约 13%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.